SkinBioTherapeutics
SBTX · AIM · Health Care · mcap £16m · 5.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 22 Sep 26 | Trading update | Trading Statement
22 September 2026 – SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health announces that both the former interim CEO, Rachel Parsonage and former acting Chair, Alyson Levett have agreed t |
−16.7% |
| 24 Aug 26 | Board change | Appointment of Interim CFO
24 August 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Anita Slater as Interim CFO (non-Board) for an initial six-month term. |
+0.0% |
| 27 Jul 26 | Holding | Holding(s) in Company | |
| 21 Jul 26 | Holding | Holding(s) in Company | |
| 29 Jun 26 | IMC Presentation Statement
29 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform (see |
−8.2% | |
| 25 Jun 26 | Board change | Directorate Change
25 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that Emily Bertram, Chief Financial Officer, has decided to leave the business on 30 June 2026. |
−2.2% |
| 23 Jun 26 | Notice of Investor Presentation
23 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life sciences business focused on skin health, will be presenting to shareholders at 9am BST on Monday 29 June 2026. |
+0.0% | |
| 08 Jun 26 | Restoration - SkinBioTherapeutics PLC
Trading on AIM for the under-mentioned securities was temporarily suspended. |
−17.9% | |
| 08 Jun 26 | Results | Half-year Results (HY26) and Restated FY25 Results
Unaudited Half Year Results and Restated unaudited FY25 Results |
−17.9% |
| 28 May 26 | Update on Investigation, Interims and Auditors
28 May 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that its investigation into, inter alia, the financial statements for the year ended 30 June 20 |
+0.0% | |
| 12 May 26 | Holding | Holding(s) in Company | |
| 29 Apr 26 | Update on the FRP Investigation
29 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that FRP Advisory is in the final stages of its forensic investigation and is expected to pro |
+0.0% | |
| 01 Apr 26 | Holding | Holding(s) in Company | |
| 01 Apr 26 | Suspension - Skinbiotherapeutics plc
Trading on AIM for the under-mentioned securities has been temporarily suspended from 01/04/2026 7:30am, pending publication of the Company's half-yearly report. |
+0.0% | |
| 01 Apr 26 | Statement re. Suspension
1 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that trading in the Company's ordinary shares will be suspended with effect from 7.30am today |
+0.0% | |
| 20 Mar 26 | Update On Board Investigation and Interims Date
· HY26 results to be delayed until Board Investigation is complete |
−34.9% | |
| 13 Mar 26 | Holding | Holding(s) in Company | |
| 09 Mar 26 | Board change | Appointment of the Interim CEO to the Board
Appointment of the Interim CEO to the SBTX Board of Directors |
−6.0% |
| 02 Mar 26 | Board change | Appointment of Interim CEO
2 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Rachel Parsonage as Interim CEO for a period of six months, during which time she will also serve as a |
+16.5% |
| 20 Feb 26 | Independent Investigation Appointment
20 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that it has appointed its new Non-Executive Director and Chair of the Audit Committee, Aly |
−9.6% | |
| 16 Feb 26 | Update on Board Investigation
· Very recent new information has led the Board to seek the reversal of all accrued royalty income from the audited FY25 revenues |
−51.5% | |
| 13 Feb 26 | Board change | Resignation of CEO
Resignation of CEO And Changes in Leadership Responsibilities |
−36.5% |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 11 Feb 26 | Routine | Issue of Equity and Total Voting Rights | |
| 29 Jan 26 | Holding | Holding(s) in Company | |
| 22 Jan 26 | Routine | Total Voting Rights | |
| 20 Jan 26 | Holding | Holding(s) in Company | |
| 20 Jan 26 | Routine | Issue of Equity and Total Voting Rights | |
| 15 Jan 26 | Holding | Holding(s) in Company | |
| 07 Jan 26 | Holding | Holding(s) in Company | |
| 05 Jan 26 | Board change | Directorate Change
5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces the appointment of Alyson Levett as new non-executive director and Chair of the Audit Committee and the promotio |
+1.5% |
| 29 Dec 25 | Routine | Result of AGM | |
| 29 Dec 25 | Holding | Holding(s) in Company | |
| 18 Dec 25 | Reconfirmation of Market Guidance and AGM Q&A
Reconfirmation of Market Guidance and AGM Shareholder Information |
−2.8% | |
| 08 Dec 25 | Holding | Holding(s) in Company | |
| 08 Dec 25 | Routine | Posting of Annual Report and AGM Notice | |
| 05 Dec 25 | Results | Final Results
5 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, reports its full year results for the 12 months ended 30 June 2025. |
−9.0% |
| 26 Nov 25 | Holding | Holding(s) in Company | |
| 19 Nov 25 | Holding | Holding(s) in Company | |
| 04 Nov 25 | Holding | Holding(s) in Company | |
| 14 Oct 25 | Board change | Directorate Change
14 October 2025 - the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces that Simon Hewitson, an Executive Director on the Board and Chief Operating Officer o |
−0.9% |
| 13 Oct 25 | Holding | Holding(s) in Company | |
| 06 Oct 25 | Superdrug first phase of store locations
Superdrug first phase of store locations for AxisBiotix™ launch in the UK |
+0.0% |
Company filings. Not investment advice.